Nuclea, SUNY College to Develop Nanochip for Cancer Diagnosis | GenomeWeb

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and the College of Nanoscale Science & Engineering (CNSE) of the State University of New York on Thursday announced a $1 million research partnership to develop and commercialize a high-throughput nanochip to analyze biomarkers associated with cancer.

The partnership is aimed at accelerating the diagnosis and treatment of breast, colon, prostate, and other cancers, they said. The partners plan to develop a nanochip based on Nuclea's antibody protein analysis chip for fatty acid synthase analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.